Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2026-05-15 Annual Report
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Group of companies' accounts made up to 2025-12-31
Annual Report Classification · 91% confidence The document is the full annual report and financial statements for Genflow Biosciences plc for the year ended 31 December 2025, containing the Chairperson’s Statement, Strategic Report, Directors’ Report, Auditor’s Report, full financial statements (balance sheet, income statement, cash flows) and notes. This aligns with the definition of an Annual Report (10-K). FY 2025
2026-05-15 English
Annual financial statements 2025
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025' and contains detailed sections typical of an annual report, including Chairperson's Statement, Strategic Report, Directors' Report, Corporate Governance Report, Audit Committee Report, Independent Auditor's Report, and full financial statements with notes. The content includes comprehensive financial data, operational updates, strategic progress, funding details, and outlook, all consistent with a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-05-13 English
Annual financial statements 2025
Annual Report Classification · 98% confidence The document is clearly a full Annual Report and Financial Statements for the year ended 31 December 2025, including the Chairperson’s Report, Strategic Report, Directors’ Report, Auditor’s Report, complete financial statements and notes. It is not a brief announcement or excerpt but a comprehensive yearly report. According to the filing definitions, this corresponds to an Annual Report (10-K). FY 2025
2026-05-13 English
Exercise of Warrants and Issue of Equity
Capital/Financing Update Classification · 95% confidence The document is an announcement from Genflow Biosciences PLC regarding the exercise of warrants and the issue of new ordinary shares, including details about the number of shares issued, exercise prices, and the resulting total voting rights. It also mentions the application for admission of these shares to trading on the FCA official list and the London Stock Exchange. The content focuses on capital raising activities through warrant exercises and share issuance, which is characteristic of a Capital/Financing Update. There is no detailed financial report, earnings data, or management discussion, nor is it a regulatory certification or voting result announcement. The document length is about 5,457 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-05-08 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025' and contains detailed sections typical of an annual report, including Chairperson's Statement, Strategic Report, Directors' Report, Corporate Governance Report, Audit Committee Report, Independent Auditor's Report, and full financial statements such as Statement of Financial Position, Comprehensive Income, Changes in Shareholders' Equity, Cash Flows, and Notes to the Financial Statements. The content includes comprehensive financial data, operational updates, strategic progress, funding details, and outlook, consistent with a full annual report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or summary. Therefore, the appropriate classification is Annual Report (10-K).
2026-04-30 English
Final Results
Annual Report Classification · 95% confidence The document is a detailed announcement of the final results for the year ended 31 December 2025 by Genflow Biosciences Plc. It includes extensive financial data, operational highlights, clinical progress, funding details, and a forward-looking statement. The text references the Annual Report being available on the company's website and to be submitted to the FCA via the National Storage Mechanism, but the document itself contains substantive financial and operational information, not just a notice of report availability. The length (15,000 characters) and content indicate this is the full final results report, which aligns with an Annual Report (10-K) type filing. The document is not merely an announcement or a certification, but a comprehensive report covering the company's yearly performance and financials. FY 2025
2026-04-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.